Takotsubo Syndrome

Our cardiomyopathies guide covers the main phenotypes. Takotsubo earns its own page because it presents as an infarct, recovers in weeks, and therefore has a different rehabilitation logic — restoring confidence and capacity rather than secondary prevention for fixed coronary disease. Patients are frequently discharged having been told, in effect, that they had a heart attack that was not one.¹

Definition

Takotsubo syndrome is an acute, usually reversible left ventricular dysfunction with regional wall motion abnormality extending beyond a single coronary territory, in the absence of culprit coronary occlusion sufficient to explain it. The name comes from the Japanese octopus pot the apically ballooning ventricle resembles in systole. It is also called stress cardiomyopathy, apical ballooning syndrome, and — less usefully — broken heart syndrome.^1,2

Pathophysiology

The mechanism is incompletely settled, but the weight of evidence supports catecholamine-mediated myocardial stunning. Surges of circulating catecholamines produce direct myocyte injury, microvascular dysfunction and transient contractile failure, with the apex disproportionately affected — possibly reflecting regional differences in adrenoceptor density. Coronary arteries are typically unobstructed, though the presence of incidental coronary disease does not exclude the diagnosis.^2,3

Co-morbidities

The pattern of co-morbidity in Takotsubo differs instructively from acute coronary syndrome, and is part of why it is a distinct condition rather than a variant. Psychiatric and neurological disorders are markedly over-represented — anxiety, depression and previous psychiatric illness are present in a large minority, and acute neurological events (stroke, subarachnoid haemorrhage, seizure) can be the trigger.⁴ Chronic respiratory disease matters directly to us: an asthma or COPD exacerbation, and the high-dose beta-agonist treatment it attracts, can precipitate it. Malignancy is more common than expected. Conventional cardiovascular risk factors are present but less dominant than in coronary disease, and incidental coronary atheroma coexists in a substantial proportion without excluding the diagnosis.

Triggers and epidemiology

Around 90% of cases occur in women, most postmenopausal. An identifiable trigger is present in roughly two-thirds: emotional (bereavement, acute fear, interpersonal conflict) or physical (surgery, acute respiratory illness, sepsis, stroke, seizure, exacerbation of asthma or COPD). Physically triggered cases carry a worse prognosis than emotionally triggered ones. A meaningful minority have no identifiable trigger at all.^1,4

⏹ Relevant to a cardiorespiratory service: an acute respiratory illness can itself be the trigger, so Takotsubo occasionally appears in patients admitted under a respiratory team rather than a cardiac one.

Presentation and diagnosis

Chest pain and breathlessness, indistinguishable at presentation from acute coronary syndrome. ECG shows ST elevation or T-wave inversion with QT prolongation; troponin is raised but characteristically modest relative to the extent of wall motion abnormality, while natriuretic peptides are disproportionately high. Diagnosis requires coronary angiography to exclude culprit occlusion, with echocardiography or ventriculography demonstrating the typical ballooning pattern. Cardiac MRI helps distinguish it from myocarditis and infarction by the absence of late gadolinium enhancement. The InterTAK diagnostic criteria formalise this.^1,5

Anatomical variants exist — apical (most common), midventricular, basal ("reverse") and focal — and right ventricular involvement occurs in a minority and predicts a more complicated course.

Course and complications

Ventricular function usually normalises within days to weeks, and the condition was for many years assumed to be benign. That assumption was wrong. In-hospital complication rates are comparable to acute coronary syndrome — acute heart failure, cardiogenic shock, left ventricular outflow tract obstruction, mitral regurgitation, ventricular arrhythmia and thrombus formation. Long-term mortality and recurrence (around 1–2% per year) are both higher than in matched populations.^1,4

Management

Supportive, since there is no specific therapy of proven benefit. Heart failure treatment during the acute phase; anticoagulation where apical thrombus is present or ballooning is severe; and caution with inotropes, which may worsen outflow tract obstruction and are conceptually at odds with a catecholamine-driven condition. Beta-blockade is often used and is physiologically attractive, but has not been shown to prevent recurrence. Recognition and treatment of psychological stressors is part of management rather than an adjunct to it.²

Medications

There is no proven disease-specific therapy, which is worth stating plainly because patients often assume otherwise. Acute heart failure is treated conventionally — diuretics for congestion, cautious vasodilators. Beta-blockade is widely used and physiologically attractive in a catecholamine-driven condition, but has not been shown to prevent recurrence.² ACE inhibitors or ARBs may be associated with better outcomes in observational data. Anticoagulation is used where apical thrombus is present or ballooning is severe. ⛔ Inotropes are relatively contraindicated — adding catecholamines to a catecholamine-mediated condition is conceptually wrong and may worsen outflow tract obstruction. Most patients are discharged on fewer drugs than a post-infarct patient, and are sometimes unsettled by that.

Multi-system manifestations

Where the trigger is a systemic illness, the cardiac event is one part of a larger picture — sepsis, major surgery, acute neurological injury or a respiratory exacerbation each bring their own trajectory, and the physically-triggered cases are the ones with worse outcomes.¹ Acute complications extend beyond the heart: pulmonary oedema, cardiogenic shock, and systemic embolism from apical thrombus. Right ventricular involvement occurs in a minority and predicts a more complicated course. ⏹ The psychological dimension is not a side issue here but part of the disease mechanism, which is unusual in cardiology.

Living with Takotsubo syndrome

This is where the condition is most poorly served, and where we can contribute most. Patients are frequently left with a contradictory account: they were told they were having a heart attack, then told they were not, and many settle on the belief that nothing was really wrong. Both readings are inaccurate and both are unhelpful — the first frightens, the second invalidates a genuinely serious event. Persistent symptoms are common even after ventricular function normalises: fatigue, breathlessness, chest discomfort and reduced exercise tolerance, sometimes for months. Fear of recurrence attaches to the original trigger, so someone whose event followed bereavement may fear their own grief. Recurrence is real at roughly 1–2% per year, which justifies taking new symptoms seriously without encouraging vigilance.

Prognosis

Ventricular function recovers within days to weeks in the great majority, and that recovery is genuine. The old assumption that the condition is therefore benign was wrong. In-hospital complication rates are comparable to acute coronary syndrome, and long-term mortality and major cardiac events remain elevated relative to matched populations.^1,2 Physically-triggered cases do worse than emotionally-triggered ones; cases with no identifiable trigger sit between. Recurrence runs at about 1–2% annually. ⏹ For rehabilitation the implication is a favourable functional outlook with a real, if modest, ongoing risk — which supports confident progression alongside honest follow-up rather than either extreme.

Role of the physiotherapist

This is where practice differs most from post-infarct care.

• Explain what happened. Many patients arrive at rehabilitation believing they had a heart attack, or conversely that "nothing was really wrong" — both are distressing and both are inaccurate. A clear account of a real cardiac event with an excellent prognosis for recovery of function is itself therapeutic.
• Exercise is safe once function has recovered, and can usually progress more freely than after infarction because there is no fixed obstructive lesion limiting supply. Re-imaging typically confirms recovery before or during the rehabilitation period.
• Screen for anxiety, depression and post-traumatic stress. Given that the syndrome is stress-triggered, psychological morbidity is high and is directly relevant to recurrence risk. Refer where indicated.
• Do not simply transplant the secondary-prevention script. Lipid and antiplatelet counselling framed around coronary plaque is not the point here, and delivering it implies a diagnosis the patient does not have.
• Watch for recurrence. New chest pain or breathlessness after a fresh stressor warrants assessment, not reassurance.

Delivery is otherwise through standard cardiorespiratory rehabilitation.

Warning signs

Part 1 · References

1. Ghadri JR, Wittstein IS, Prasad A, et al. International expert consensus document on Takotsubo syndrome (part I): clinical characteristics, diagnostic criteria and pathophysiology. Eur Heart J 2018;39(22):2032–2046.
2. Ghadri JR, Wittstein IS, Prasad A, et al. International expert consensus document on Takotsubo syndrome (part II): diagnostic workup, outcome and management. Eur Heart J 2018;39(22):2047–2062.
3. Wittstein IS, Thiemann DR, Lima JA, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 2005;352(6):539–548.
4. Templin C, Ghadri JR, Diekmann J, et al. Clinical features and outcomes of Takotsubo (stress) cardiomyopathy. N Engl J Med 2015;373(10):929–938.
5. Lyon AR, Citro R, Schneider B, et al. Pathophysiology of Takotsubo syndrome: JACC state-of-the-art review. J Am Coll Cardiol 2021;77(7):902–921.

References are numbered in citation order (Vancouver/BMJ style) and were current at the time of writing. Guidelines are living documents — verify against the latest version before clinical use.